In Cancer Biology,
Context Matters

Uncover immunotherapy biomarkers by visualizing the tumor microenvironment in context

We’ve rebranded some of our products, learn more ›

CODEX is now PhenoCycler
Phenoptics is now Phenolmager

Unmet Need in Cancer Immunotherapy

Despite the progress we’ve made in cancer immunotherapy, response rates continue to remain in the 20 to 30% range. There’s a need for biomarkers that can accurately predict response to treatment.

clinical-illustration-480x435-1.png

Understanding Cancer-Immune Biology​

Immunotherapy treatments rely on the activation of the immune system to fight and kill tumor cells. The key to understanding more about tumor-immune biology lies in studying the complexity of the tumor microenvironment.

Transforming Your Approach to Cancer Biomarker Discovery

Multispectral Imaging enables the discovery of biomarker signatures from a single FFPE tissue section, while preserving the spatial context of the tumor microenvironment.

icon-Visualize.png

Visualize

See how cells organize and interact in the tumor microenvironment
icon-Quantify.png

Quantify

Shift the paradigm from subjective IHC measurements to quantitative, reproducible multiplex imaging
icon-Predict.png

Predict

Reliably predict immunotherapy response and disease progression through novel biomarker signatures

Spatial Phenotypic Signatures - Predicting Immunotherapy Response

Nav title #1
A New Biomarker Class in the Tumor Microenvironment
Spatial Phenotypic Signatures (SPS) measure the
Interactions and Cell Densities
Of Tumor and Immune Cells
in the tumor microenvironment.
Nav title #1
Nav title #3
Measuring Spatial Phenotypic Signatures
Spatial Phenotypic Signatures can be
accurately measured with
MULTIPLEX IMAGING
Nav title #3
Nav title #4
Better Predictive Capabilities and Reproducibility
A multi-institutional study found that mIF had
Higher Predictive Accuracy
than PD-L1 IHC and genomic biomarkers.
Nav title #4
Nav title #5
Saving Precious Time and Tissue Samples
With multiplex imaging, you can:
Analyze dozens of cell phenotypes and their spatial interactions from a
SINGLE FFPE TISSUE SECTION
Process
25 to 30 SAMPLES PER DAY
Nav title #5

Oncology Experts Discover Spatial Phenotypic Signatures with Multiplex Imaging

Standardization Efforts​

The value of Spatial Phenotypic Signatures in translational and clinical research relies on a standardized and reproducible workflow.

MITRE: First Multi-Site mIF Standardization Study

6 leading institutions, across academia and pharma, established the inter- and intra-site reproducibility of the Phenoptics multiplex imaging workflow.

Validating Multiplex Imaging Panels for PD-L1 Testing

Studies by pathologists at Queen’s University show high concordance between DAB IHC and multispectral imaging panels for profiling immunotherapy biomarkers.

Bringing Multiplex Imaging to the Clinic

Dr. Joe Yeong, Immunopathologist at the Singapore General Hospital predicts that multiplex imaging is poised to transform the cancer biomarker landscape.

What's New

Immune Biomarker Trailblazer at Columbia University Validates mIF Workflow for Melanoma

The Tumor Neighborhood Watch

Queen's University Offers Comprehensive Opal Multiplex Optimization and Validation Protocols

Would You Like to Implement
mIF-Based Spatial Phenotypic Signatures in Your Research?